Previous 10 | Next 10 |
Gainers: Sonoma Pharmaceuticals (SNOA) +114%. NantHealth (NH) +110%. vTv Therapeutics (VTVT) +59%. aTyr Pharma (LIFE) +33%. NantKwest (NK) +22%.Losers: SELLAS Life Sciences (SLS) -33%. Immutep (IMMP) -29%. Salarius Pharmaceuticals (SLRX) -29%. Nabriva Therapeutics (NBRV) -29%. ALX O...
Nabriva Therapeutics NBRV -30% after priced $15M public offering.Aytu BioScience (AYTU) -25% on raising 'bought deal' offering to $25M.Immutep (IMMP) -24%.Professional Diversity Network (IPDN) -24%.SELLAS Life Sciences Group SLS -21% after announcing positiv...
Gainers: Immutep (IMMP) +166%.SELLAS Life Sciences (SLS) +90%.Neos Therapeutics (NEOS) +65%.Greenwich LifeSciences (GLSI) +51%.Aytu BioScience (AYTU) +34%.Veru (VERU) +34%.Silver Spike Acquisition (SSPK) +32%.8x8 (EGHT) +32%.TG Therapeutics (TGTX) +31%.Peabody Energy (BTU) +29%...
Gainers: Immutep (IMMP) +204%, Greenwich LifeSciences (GLSI) +60%, TG Therapeutics (TGTX) +37%, SELLAS Life Sciences (SLS) +28%, Anixa Biosciences (ANIX) +18%.Losers: Xenetic Biosciences (XBIO) -32%, Oncternal Therapeutics (ONCT)-26%, GeoVax L...
Immutep (IMMP) +132% after breast cancer trial shows promising survival data.Greenwich LifeSciences (GLSI) +57%.UTStarcom Holdings (UTSI) +50%.Panbela Therapeutics (PBLA) +46%.Leju Holdings (LEJU) +38%.SELLAS Life Sciences (SLS) +36%.ClearOne (CLRO) +35% to expand its footprint in M...
Cancer Stocks Are Surging This Week Cancer penny stocks took off this week thanks to a little help from one of the small caps making headlines. This morning, Greenwich LifeSciences ( GLSI Stock Report ) announced big news on its cancer treatment candidate. A poster presentat...
Immutep (IMMP) skyrockets post-market after reporting a statistically significant survival benefit in data from the ongoing Phase 2B AIPAC study evaluating its lead product candidate eftilagimod alpha in combination with paclitaxel chemotherapy in patients with metastatic breast cancer.The co...
New randomised, double-blind, placebo-controlled phase II clinical study to commence in Q1 CY2021 Evaluates the efficacy and safety of eftilagimod alpha in combination with paclitaxel chemotherapy, compared to placebo plus paclitaxel (as per AIPAC study) Fully funded by EOC Pharma...
Gainers: [[IMMP]] +105%. [[UTSI]] +87.9%. [[ASAN]] +16.1%. [[CELP]] +13.4%. [[MESA]] +10.4%.Losers: [[LEAF]] -15.8%. [[QIWI]] -15%. [[PXLW]] -10%. [[NTN]] -8.3%. [[PXLW]] -6%. For further details see: ASAN, PXLW, QIWI and IMMP among after-hours movers
First time an antigen presenting cell (APC) activator has shown an Overall Survival (OS) benefit in a randomised setting in metastatic breast cancer patients known to be insensitive to immune checkpoint inhibitor therapy Promising and improving overall trend in OS in total population ...
News, Short Squeeze, Breakout and More Instantly...
Media Release Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing no...
2024-07-12 10:45:04 ET QuantumScape Corp (QS) QS is trading UP for the last 5 days, and it at trading at $7.84 with volume of 22,322,158 and a one day change of $0.78 (10.98%). QuantumScape Corp has a 52-week low of 4.67 and a 52-week high of $13.86. The business's 50-day moving ave...
Media Release Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatment approach not containing chemotherapy in patients with CPS <1 High complete response...